Please login to the form below
US Biomedical Advanced Research and Development Authority
This page shows the latest US Biomedical Advanced Research and Development Authority news and features for those working in and with pharma, biotech and healthcare.
FDA briefing document backs J&J’s one-dose COVID-19 vaccine
In the US, the efficacy rate increased slightly to 72%, while in Latin America and South Africa the vaccine was 66% and 57% effective, respectively. ... Under the terms of the deal, the US Biomedical Advanced Research and Development Authority (BARDA)
Latest news
-
J&J’s one-dose COVID-19 vaccine proves 66% effective in phase 3 trial
In the US, the efficacy rate was 72% while in Latin America and South Africa the vaccine was 66% and 57% effective, respectively. ... Under the terms of the deal, the US Biomedical Advanced Research and Development Authority (BARDA) and the US Department
-
J&J could launch its single-dose COVID-19 vaccine in March
US pharma Johnson &Johnson (J&J) is planning to launch its single-dose COVID-19 vaccine in March, according to the company’s chief scientific officer Paul Stoffels. ... The phase 3 ENSEMBLE trial was launched in collaboration with the US Department of
-
J&J completes enrolment for late-stage COVID-19 vaccine trial
The phase 3 ENSEMBLE trial is being conducted in collaboration with the US Biomedical Advanced Research and Development Authority (BARDA) and the National Institute of Allergy and Infectious Diseases (NIAID). ... This trial is currently enrolling
-
EMA launches rolling review of J&J’s COVID-19 vaccine
The pharma giant is initiating the phase 3 ENSEMBLE trial in collaboration with the US Department of Health and Human Services’ (HHS), Biomedical Advanced Research and Development Authority (BARDA) and the ... US National Institute of Allergy and
-
Regeneron’s COVID-19 antibody cocktail scores FDA emergency approval
A COVID-19 antibody cocktail developed by Regeneron has been given an emergency use authorisation (EUA) from the US Food and Drug Administration (FDA). ... Regeneron has already signed a manufacturing and supply agreement with the US Biomedical Advanced
More from news
Approximately 0 fully matching, plus 23 partially matching documents found.
Latest Intelligence
-
Rethinking our approach to infectious disease preparedness
So we need long-term strategic investment so that we have therapies and vaccines under development – and the infrastructure to support them, from governments and the private sector – in the vital ... Achaogen and Aradigm filed for bankruptcy in 2019,
-
Developing a COVID-19 vaccine
The phase 1 study, which is being conducted by the US National Institutes of Health (NIH) at Kaiser Permanente Washington Health Research Institute in Seattle, aims to recruit 45 healthy men ... That includes an agreement with the US Biomedical Advanced
-
Deal Watch June 2016
One of the companies developing pathogen reduction systems for donated blood, Cerus Corporation, signed an agreement in June worth up to $180m with the US Biomedical Advanced Research and Development Authority ... Includes rights to sublicense outside
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Lead Market Access Writer, £5K joining bonus, UK
-
Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
-
Highly competitive salary
- Exciting Medical Writer Career Opportunity for Postdoc, Medcomms
-
Highly competitive salary
- Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...
-
Highly competitive salary
- World Health Organization releases latest set of COVID-19 guidelines
- Europe’s cancer community publishes new report on transforming patient care
- BeiGene’s Brukinsa receives FDA approval for chronic lymphocytic leukaemia
- AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer
- Eli Lilly announces $450m investment in US manufacturing site
- EU outlines measures to mitigate antibiotic shortage across Europe
- Innovative Trials comments on extra funding to increase access to clinical trials for cancer patients
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- JCVI recommends autumn COVID-19 vaccine booster for those at highest risk
- MIT researchers develop AI model to detect future lung cancer risk
- Merging global and local pharmacovigilance operations into a successful integrated approach
- Diversifying Healthcare AI with Federated Learning
- FDA and CDC investigate potential safety concern for Pfizer/BioNTech’s COVID-19 vaccine
- World Health Organization releases latest set of COVID-19 guidelines
- AbbVie and Eli Lilly leave UK’s voluntary drug pricing agreement
- AbbVie trial backs chemo-free Imbruvica combo regimen
- AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer
- EU to revise pharmaceuticals law amid antibiotic shortages
PMHub
Wisepress
Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...
Latest intelligence
- Virtual Steering Committee & Peer Influence Program
- In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....
- Meeting healthcare’s rising challenges
- The journey to discover novel therapies through digital innovation and ensure scientific advances achieve their potential...
- Report gives insights to address gaps in HCP engagement
- How does Pharma-HCP engagement need to evolve in today's digital landscape?...
